Short answer
Kura Oncology, Inc. (KURA) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026.
Kura Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial and operational details
Item EX-99.1 · Exhibit EX-99.1
- KOMZIFTI revenue reached $9.1M, up 57% sequentially, with approximately 115 new patient starts, up 35%
- Majority share of new starts in R/R NPM1-mutated AML supports early commercial leadership after two full launch quarters
- Frontline data showed CRc rates of 96% in NPM1-mutated AML and 90% in KMT2A-rearranged AML
- Cash and short-term investments totaled $519.0M, plus $180M anticipated Kyowa Kirin payments, funding AML development through anticipated 2028 Phase 3 results
- Net loss widened to $68.3M from $66.1M as SG&A increased to $31.8M and stock-based compensation reached $8.2M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kura Oncology, Inc. 8-K filings
Get the next KURA 8-K as it lands
Follow KURA for push alerts, or ask the research agent what this filing means.